Skip to main content
Erschienen in: Inflammation 3/2014

01.06.2014

The Relationship Between Serum Lipoprotein (a) Levels and Ischemic Stroke Risk: A Cohort Study in the Chinese Population

verfasst von: Shao-yi Li, Yun Gao, Wei-ning Ma, Hua-chao Wang, Gang Zhou, Wen-chang Guo, Yun-hui Liu

Erschienen in: Inflammation | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The role of atherosclerosis in ischemic stroke has been intensively investigated in recent years, and lipoprotein (a) [Lp(a)] is found to have roles during the process. The aim of this study was to investigate the relationship between acute ischemic stroke (AIS) and serum Lp(a) levels in the Chinese population. All consecutive patients with first-ever acute ischemic stroke during 2011–2012 were recruited to participate in the study. Serum Lp(a) levels and routine tests were examined in both groups. The National Institutes of Health Stroke Scale (NIHSS) score was assessed on admission blinded to Lp(a) levels. In this study, 181 patients with acute ischemic stroke were included. There was a significant difference in median serum Lp(a) levels between acute ischemic stroke patients and control cases (328 [IQR, 173–554] vs. 145 [IQR, 66–254] mg/L, respectively; P = 0.000). Lp(a) levels increased with increasing severity of stroke as defined by the NIHSS score (P = 0.000). For the entire group, when adjusting for other possible risk factors, an elevated Lp(a) level was an independent risk factor for stroke, and a serum Lp(a) level ≥300 mg/L was associated with a 2.23-fold increase in AIS (P = 0.015). In addition, this association was stronger in male than in female patients. High Lp(a) levels are significantly related to stroke, independent from other traditional and emerging risk factors, suggesting that they may play a role in its pathogenesis. It should be considered as a routine risk factor for stroke in the Chinese population.
Literatur
1.
Zurück zum Zitat Vucković, B.A., M.J. Djerić, T.A. Ilić, V.B. Canak, S.L.J. Kojić-Damjanov, M.G. Zarkov, and V.S. Cabarkapa. 2010. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Srpski Arhiv za Celokupno Lekarstvo 138(1): 12–17.PubMed Vucković, B.A., M.J. Djerić, T.A. Ilić, V.B. Canak, S.L.J. Kojić-Damjanov, M.G. Zarkov, and V.S. Cabarkapa. 2010. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Srpski Arhiv za Celokupno Lekarstvo 138(1): 12–17.PubMed
2.
Zurück zum Zitat Tu, W.J., X. Dong, S.J. Zhao, D.G. Yang, and H. Chen. 2013. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. Journal of Neuroendocrinology 25: 771–778.PubMedCrossRef Tu, W.J., X. Dong, S.J. Zhao, D.G. Yang, and H. Chen. 2013. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. Journal of Neuroendocrinology 25: 771–778.PubMedCrossRef
3.
Zurück zum Zitat Unal, E., S. Mungan, S. Bilen, Y. Karadag, N. Oztekin, F. Bakir, and F. Ak. 2013. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. International Journal of Neuroscience 123: 532–536.PubMedCrossRef Unal, E., S. Mungan, S. Bilen, Y. Karadag, N. Oztekin, F. Bakir, and F. Ak. 2013. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. International Journal of Neuroscience 123: 532–536.PubMedCrossRef
4.
Zurück zum Zitat Uno, M., K.T. Kitazato, K. Nishi, H. Itabe, and S. Nagahiro. 2003. Raised plasma oxidized LDL in acute cerebral infarction. Journal of Neurology, Neurosurgery and Psychiatry 74: 312–316.PubMedCentralPubMedCrossRef Uno, M., K.T. Kitazato, K. Nishi, H. Itabe, and S. Nagahiro. 2003. Raised plasma oxidized LDL in acute cerebral infarction. Journal of Neurology, Neurosurgery and Psychiatry 74: 312–316.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Nordestgaard, B.G., M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen. 2010. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31: 2844–2853.PubMedCentralPubMedCrossRef Nordestgaard, B.G., M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen. 2010. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31: 2844–2853.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Morishita, R., J. Ishii, Y. Kusumi, S. Yamada, N. Komai, M. Ohishi, M. Nomura, H. Hishida, M. Niihashi, and M. Mitsumata. 2009. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. Journal of Atherosclerosis and Thrombosis 16: 410–418.PubMedCrossRef Morishita, R., J. Ishii, Y. Kusumi, S. Yamada, N. Komai, M. Ohishi, M. Nomura, H. Hishida, M. Niihashi, and M. Mitsumata. 2009. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. Journal of Atherosclerosis and Thrombosis 16: 410–418.PubMedCrossRef
7.
Zurück zum Zitat Rosas, S., M. Joffe, M. Wolfe, K. Brayman, and D.J. Rader. 2008. Effects of renal replacement therapy on plasma lipoprotein(a) levels. American Journal of Nephrology 28: 361–365.PubMedCentralPubMedCrossRef Rosas, S., M. Joffe, M. Wolfe, K. Brayman, and D.J. Rader. 2008. Effects of renal replacement therapy on plasma lipoprotein(a) levels. American Journal of Nephrology 28: 361–365.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J.L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263: 35–36.PubMedCrossRef Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J.L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263: 35–36.PubMedCrossRef
9.
Zurück zum Zitat Wright, L.C., D.R. Sullivan, M. Muller, M. Dyne, M.H. Tattersall, and C.E. Mountford. 1989. Elevated apolipoprotein(a) levels in cancer patients. International Journal of Cancer 43: 241–244.CrossRef Wright, L.C., D.R. Sullivan, M. Muller, M. Dyne, M.H. Tattersall, and C.E. Mountford. 1989. Elevated apolipoprotein(a) levels in cancer patients. International Journal of Cancer 43: 241–244.CrossRef
10.
Zurück zum Zitat Engler, H., and W.F. Riesen. 1993. Effect of thyroid function on concentrations of lipoprotein(a). Clinical Chemistry 39: 2466–2469.PubMed Engler, H., and W.F. Riesen. 1993. Effect of thyroid function on concentrations of lipoprotein(a). Clinical Chemistry 39: 2466–2469.PubMed
11.
Zurück zum Zitat Milionis, H.J., V. Mittari, G. Exarchakos, R. Kalaitzidis, A.T. Skevas, and M.S. Elisaf. 2003. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. European Journal of Clinical Investigation 33: 1045–1050.PubMedCrossRef Milionis, H.J., V. Mittari, G. Exarchakos, R. Kalaitzidis, A.T. Skevas, and M.S. Elisaf. 2003. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. European Journal of Clinical Investigation 33: 1045–1050.PubMedCrossRef
12.
Zurück zum Zitat Bernick, C., L. Kuller, C. Dulberg, et al. 2001. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57: 1222–1229.PubMedCrossRef Bernick, C., L. Kuller, C. Dulberg, et al. 2001. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57: 1222–1229.PubMedCrossRef
13.
Zurück zum Zitat Safarova, M.S., M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky. 2013. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements 14: 93–99.PubMedCrossRef Safarova, M.S., M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky. 2013. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements 14: 93–99.PubMedCrossRef
14.
Zurück zum Zitat Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 2219–2226.PubMedCentralPubMedCrossRef Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 2219–2226.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Smolders, B., R. Lemmens, and V. Thijs. 2007. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 38: 1959–1966.PubMedCrossRef Smolders, B., R. Lemmens, and V. Thijs. 2007. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 38: 1959–1966.PubMedCrossRef
16.
Zurück zum Zitat Boden-Albala, B., D.E. Kargman, I.F. Lin, M.C. Paik, R.L. Sacco, and L. Berglund. 2010. Increased stroke risk and lipoprotein (a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovascular Diseases 30: 237–243.PubMedCentralPubMedCrossRef Boden-Albala, B., D.E. Kargman, I.F. Lin, M.C. Paik, R.L. Sacco, and L. Berglund. 2010. Increased stroke risk and lipoprotein (a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovascular Diseases 30: 237–243.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Ariyo, A.A., C. Thach, and R. Tracy. 2003. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef Ariyo, A.A., C. Thach, and R. Tracy. 2003. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef
19.
Zurück zum Zitat Ohira, T., P. Schreiner, J. Morrisett, L. Chambless, W. Rosamond, and A. Folsom. 2006. Lipoprotein(a) and incident ischemic stroke: the Atherosclerotic Risk in Communities (ARIC) study. Stroke 37: 1407–1412.PubMedCrossRef Ohira, T., P. Schreiner, J. Morrisett, L. Chambless, W. Rosamond, and A. Folsom. 2006. Lipoprotein(a) and incident ischemic stroke: the Atherosclerotic Risk in Communities (ARIC) study. Stroke 37: 1407–1412.PubMedCrossRef
20.
Zurück zum Zitat Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein (a) and coronary heart disease. Meta analysis of prospective studies. Circulation 102: 1082–1085.PubMedCrossRef Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein (a) and coronary heart disease. Meta analysis of prospective studies. Circulation 102: 1082–1085.PubMedCrossRef
21.
Zurück zum Zitat Alfthan, G., J. Pekkanen, M. Jauhiainen, J. Pitkäniemi, M. Karvonen, J. Tuomilehto, J.T. Salonen, and C. Ehnholm. 1994. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9–19.PubMedCrossRef Alfthan, G., J. Pekkanen, M. Jauhiainen, J. Pitkäniemi, M. Karvonen, J. Tuomilehto, J.T. Salonen, and C. Ehnholm. 1994. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9–19.PubMedCrossRef
22.
Zurück zum Zitat Ridker, P.M., M.J. Stampfer, and C.H. Hennekens. 1995. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269–1273.PubMedCrossRef Ridker, P.M., M.J. Stampfer, and C.H. Hennekens. 1995. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269–1273.PubMedCrossRef
23.
Zurück zum Zitat Hatano, S. 1976. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 54: 541–553.PubMedCentralPubMed Hatano, S. 1976. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 54: 541–553.PubMedCentralPubMed
24.
Zurück zum Zitat Katan, M., F. Fluri, and N.G. Morgenthaler. 2009. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Annals of Neurology 66: 799–808.PubMedCrossRef Katan, M., F. Fluri, and N.G. Morgenthaler. 2009. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Annals of Neurology 66: 799–808.PubMedCrossRef
25.
Zurück zum Zitat Brott, T., J.R. Marler, C.P. Olinger, et al. 1989. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 20: 871–875.PubMedCrossRef Brott, T., J.R. Marler, C.P. Olinger, et al. 1989. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 20: 871–875.PubMedCrossRef
26.
Zurück zum Zitat Adams Jr., H.P., B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, and E.E. Marsh 3rd. 1993. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.PubMedCrossRef Adams Jr., H.P., B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, and E.E. Marsh 3rd. 1993. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.PubMedCrossRef
27.
Zurück zum Zitat Kamstrup, P.R., A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331–2339.PubMedCrossRef Kamstrup, P.R., A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331–2339.PubMedCrossRef
28.
Zurück zum Zitat Matthews, K.A., M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak. 2005. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). American Heart Journal 149: 1066–1073.PubMedCrossRef Matthews, K.A., M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak. 2005. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). American Heart Journal 149: 1066–1073.PubMedCrossRef
29.
Zurück zum Zitat Tu, W.J., S.J. Zhao, T.G. Liu, D.G. Yang, and H. Chen. 2013. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurological Research 35: 912–921.PubMedCrossRef Tu, W.J., S.J. Zhao, T.G. Liu, D.G. Yang, and H. Chen. 2013. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurological Research 35: 912–921.PubMedCrossRef
30.
Zurück zum Zitat Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef
31.
Zurück zum Zitat Kistorp, C., I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt. 2005. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609–1616.PubMedCrossRef Kistorp, C., I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt. 2005. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609–1616.PubMedCrossRef
32.
Zurück zum Zitat Wiberg, B., J. Sundstrom, J. Arnlov, A. Terent, B. Vessby, B. Zethelius, and L. Lind. 2006. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. Stroke 37: 2898–2903.PubMedCrossRef Wiberg, B., J. Sundstrom, J. Arnlov, A. Terent, B. Vessby, B. Zethelius, and L. Lind. 2006. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. Stroke 37: 2898–2903.PubMedCrossRef
33.
Zurück zum Zitat Dhamija, R.K., P. Gaba, S. Arora, A. Kaintura, M. Kumar, and J. Bhattacharjee. 2009. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. Journal of Neurological Sciences 281: 64–68.CrossRef Dhamija, R.K., P. Gaba, S. Arora, A. Kaintura, M. Kumar, and J. Bhattacharjee. 2009. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. Journal of Neurological Sciences 281: 64–68.CrossRef
34.
Zurück zum Zitat Hachinski, V., C. Graffagnino, M. Beaudry, et al. 1996. Lipids and stroke paradox resolved. Archives of Neurology 53: 303–308.PubMedCrossRef Hachinski, V., C. Graffagnino, M. Beaudry, et al. 1996. Lipids and stroke paradox resolved. Archives of Neurology 53: 303–308.PubMedCrossRef
35.
Zurück zum Zitat van Kooten, F., J. van Krimpen, D.W. Dippel, N. Hoogerbrugge, and P.J. Koudstaal. 1996. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 27: 1231–1235.PubMedCrossRef van Kooten, F., J. van Krimpen, D.W. Dippel, N. Hoogerbrugge, and P.J. Koudstaal. 1996. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 27: 1231–1235.PubMedCrossRef
36.
Zurück zum Zitat Ariyo, A.A., C. Thach, and R. Tracy. 2003. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef Ariyo, A.A., C. Thach, and R. Tracy. 2003. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef
37.
Zurück zum Zitat Hajjar, K.A., and D. Gavish. 1989. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339: 303–305.PubMedCrossRef Hajjar, K.A., and D. Gavish. 1989. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339: 303–305.PubMedCrossRef
38.
Zurück zum Zitat Boerwinkle, E., C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. Journal of Clinical Investigation 90: 52–60.PubMedCentralPubMedCrossRef Boerwinkle, E., C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. Journal of Clinical Investigation 90: 52–60.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Tascilar, N., S. Ekem, and E. Aciman. 2009. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in Turkish population. Tohoku Journal of Experimental Medicine 218: 293–300.PubMedCrossRef Tascilar, N., S. Ekem, and E. Aciman. 2009. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in Turkish population. Tohoku Journal of Experimental Medicine 218: 293–300.PubMedCrossRef
40.
Zurück zum Zitat Rath, M., A. Niendorf, T. Reblin, M. Dietel, H.J. Krebber, and U. Beisiegel. 1989. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579–592.PubMedCrossRef Rath, M., A. Niendorf, T. Reblin, M. Dietel, H.J. Krebber, and U. Beisiegel. 1989. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579–592.PubMedCrossRef
41.
Zurück zum Zitat Kim, B.S., H.S. Jung, O.Y. Bang, C.S. Chung, K.H. Lee, and G.M. Kim. 2010. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 212: 682–688.PubMedCrossRef Kim, B.S., H.S. Jung, O.Y. Bang, C.S. Chung, K.H. Lee, and G.M. Kim. 2010. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 212: 682–688.PubMedCrossRef
42.
Zurück zum Zitat Von Depka, M., U. Nowka-Göttl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth. 2000. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96: 3364–3368. Von Depka, M., U. Nowka-Göttl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth. 2000. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96: 3364–3368.
43.
Zurück zum Zitat Barre, D.E., O. Griscti, K.A. Mizier-Barre, and K. Hafez. 2005. Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia. Canada. Journal of Oleo Science 54: 347–354.CrossRef Barre, D.E., O. Griscti, K.A. Mizier-Barre, and K. Hafez. 2005. Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia. Canada. Journal of Oleo Science 54: 347–354.CrossRef
44.
Zurück zum Zitat Dangas, G., R. Mehran, P.C. Harpel, et al. 1998. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. Journal of the American College of Cardiology 32: 2035–2042.PubMedCrossRef Dangas, G., R. Mehran, P.C. Harpel, et al. 1998. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. Journal of the American College of Cardiology 32: 2035–2042.PubMedCrossRef
45.
Zurück zum Zitat Ohtahara, A., I. Hisatome, Y. Yamamoto, M. Furuse, K. Sonoyama, Y. Furuse, et al. 2001. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. Journal of Hypertension 19: 575–582.PubMedCrossRef Ohtahara, A., I. Hisatome, Y. Yamamoto, M. Furuse, K. Sonoyama, Y. Furuse, et al. 2001. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. Journal of Hypertension 19: 575–582.PubMedCrossRef
46.
Zurück zum Zitat Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS 1992:10193–10197. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS 1992:10193–10197.
Metadaten
Titel
The Relationship Between Serum Lipoprotein (a) Levels and Ischemic Stroke Risk: A Cohort Study in the Chinese Population
verfasst von
Shao-yi Li
Yun Gao
Wei-ning Ma
Hua-chao Wang
Gang Zhou
Wen-chang Guo
Yun-hui Liu
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9785-x

Weitere Artikel der Ausgabe 3/2014

Inflammation 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.